// App-Quantinova.ai

P2-02-17 : T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

Researchers

Presenter

  • Bidard F-C

Principal Investigators

  • Romieu G

  • Jacot W

  • Bollet M

  • Bourgeois H

  • Renaud N

  • Pelissier S

  • Armanet S

  • Baeten K

  • Pierga J-Y

  • Cottu P

  • Dieras V

  • Lerebours F

  • Servent V

  • Luporsi E

  • Lortholary A

  • Tubiana-Mathieu N

  • Espie M

Medical Centers

  • Clinique Victor Hugo, Le Mans, France

  • Institut de Cancerologie Hartmann, Levallois-Perret, France

  • Institut du Cancer de Montpellier, Montpellier, France

  • Institut Curie, Paris Cedex, France

  • Centre Oscar Lambret, Lille, France

  • Saint-Antoine University Hospital, Paris, France

  • Centre Catherine de Sienne, Nantes, France

  • Institut de Cancerologie de Lorraine, Nancy, France

  • Limoges University Hospital, Limoges, France

Locations

  • France

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved